• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?

作者信息

Lamarca Angela, Foster Lucy, Valle Juan W, Satyadas Thomas, Siriwardena Ajith

机构信息

Department of Medical Oncology, The Christie NHS Foundation Trust; Division of Cancer Sciences, University of Manchester, Manchester, UK.

Department of Pathology, Manchester Royal Infirmary, Manchester, UK.

出版信息

ESMO Open. 2020 Oct;5(5):e000633. doi: 10.1136/esmoopen-2019-000633.

DOI:10.1136/esmoopen-2019-000633
PMID:33122352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7597489/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/230c/7597489/3d62f684563f/esmoopen-2019-000633f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/230c/7597489/3d62f684563f/esmoopen-2019-000633f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/230c/7597489/3d62f684563f/esmoopen-2019-000633f01.jpg

相似文献

1
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?FOLFIRINOX或FOLFOXIRI方案用于局部晚期十二指肠腺癌：我们是否有所遗漏？
ESMO Open. 2020 Oct;5(5):e000633. doi: 10.1136/esmoopen-2019-000633.
2
The role of the FOLFIRINOX regimen for advanced pancreatic cancer.FOLFIRINOX 方案在晚期胰腺癌中的作用。
Curr Oncol Rep. 2013 Apr;15(2):182-9. doi: 10.1007/s11912-012-0290-4.
3
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.新辅助FOLFIRINOX化疗后对交界性和局部晚期胰腺腺癌的CT评估。
Eur Radiol. 2017 Jul;27(7):3104-3116. doi: 10.1007/s00330-016-4632-8. Epub 2016 Nov 28.
4
Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?化疗：转移性胰腺癌——FOLFIRINOX方案是新标准吗？
Nat Rev Clin Oncol. 2011 Jul 5;8(8):452-3. doi: 10.1038/nrclinonc.2011.107.
5
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.氟尿嘧啶持续输注、亚叶酸钙、奥沙利铂和伊立替康（FOLFOXIRI）与氟尿嘧啶持续输注、亚叶酸钙和伊立替康（FOLFIRI）用于转移性结直肠癌一线治疗的III期试验：西北肿瘤协作组
J Clin Oncol. 2007 May 1;25(13):1670-6. doi: 10.1200/JCO.2006.09.0928.
6
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.首创新药 CPI-613 联合改良 FOLFIRINOX 方案治疗转移性胰腺癌患者的安全性和耐受性：一项单中心、开放标签、剂量递增、I 期临床试验。
Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. Epub 2017 May 8.
7
FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?FOLFIRINOX方案用于局部晚期胰腺腺癌：回归未来？
Oncologist. 2013;18(5):487-9. doi: 10.1634/theoncologist.2013-0157.
8
FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Pancreas. 2012 Aug;41(6):973-4. doi: 10.1097/MPA.0b013e3182496e90.
9
FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.FOLFIRINOX方案与放疗用于局部晚期胰腺癌：一项队列研究。
J Surg Oncol. 2018 Nov;118(6):1021-1026. doi: 10.1002/jso.25233. Epub 2018 Sep 27.
10
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.转移性胰腺癌与FOLFIRINOX方案的应用经验——来自一个发展中国家的横断面分析
Asian Pac J Cancer Prev. 2015;16(14):6001-6. doi: 10.7314/apjcp.2015.16.14.6001.

本文引用的文献

1
A pathological complete response by chemotherapy with S-1 and oxaliplatin for a locally advanced duodenal adenocarcinoma in Lynch syndrome: a case report.S-1与奥沙利铂化疗对林奇综合征局部晚期十二指肠腺癌的病理完全缓解：一例报告
Surg Case Rep. 2019 Oct 21;5(1):146. doi: 10.1186/s40792-019-0712-8.
2
Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis.BRCA1/2基因突变对胰腺癌患者生存的影响：一项病例系列分析。
Ann Hepatobiliary Pancreat Surg. 2019 May;23(2):200-205. doi: 10.14701/ahbps.2019.23.2.200. Epub 2019 May 31.
3
Molecular subtypes of pancreatic cancer.
胰腺癌的分子亚型。
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220. doi: 10.1038/s41575-019-0109-y.
4
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
5
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
6
A complete response to capecitabine and oxaliplatin chemotherapy in primary duodenal carcinoma with liver and nodal metastases: a case report.原发性十二指肠癌伴肝和淋巴结转移对卡培他滨和奥沙利铂化疗的完全缓解：一例报告
Surg Case Rep. 2018 Sep 29;4(1):125. doi: 10.1186/s40792-018-0532-2.
7
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.新辅助 FOLFIRINOX 方案治疗局部进展期和可切除边界胰腺癌：意向治疗分析。
Eur J Surg Oncol. 2018 Oct;44(10):1619-1623. doi: 10.1016/j.ejso.2018.07.057. Epub 2018 Aug 2.
8
FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer.FOLFIRINOX方案治疗使局部晚期胰腺癌达到病理完全缓解。
J Gastrointest Oncol. 2018 Apr;9(2):E9-E12. doi: 10.21037/jgo.2018.01.07.
9
Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).小肠腺癌：法国专家组临床实践指南，用于诊断、治疗和随访（SNFGE、FFCD、GERCOR、UNICANCER、SFCD、SFED、SFRO）。
Dig Liver Dis. 2018 Jan;50(1):15-19. doi: 10.1016/j.dld.2017.09.123. Epub 2017 Oct 6.
10
Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.新辅助治疗后达到病理完全缓解的可切除边缘/局部晚期胰腺腺癌患者的临床特征
Am J Clin Oncol. 2018 Oct;41(10):982-985. doi: 10.1097/COC.0000000000000409.